Kolexia
Hennequin Audrey Oncologie médicale
Hennequin Audrey
Oncologie médicale
Centre Georges-François Leclerc
Dijon, France
79 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs colorectales Tumeurs du sein triple-négatives Hypertension artérielle Tumeurs du pancréas Protéinurie Neutropénie Métastase tumorale Tumeurs de l'estomac

Collaborateurs

Voir plus
Ghiringhelli Francois
Ghiringhelli Francois
Centre Georges-François Leclerc, Dijon, France
Fumet Jean David
Fumet Jean David
Centre Georges-François Leclerc, Dijon, France
Bertaut Aurelie
Bertaut Aurelie
Centre Georges-François Leclerc, Dijon, France
Desmoulins Isabelle
Desmoulins Isabelle
Centre Georges-François Leclerc, Dijon, France

Industries

Voir plus
B3TSI
29 collaboration(s)
Dernière en 2023
A+A
6 collaboration(s)
Dernière en 2023
MSD
6 collaboration(s)
Dernière en 2023
Lilly
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
VOCANGIO: Modifications in Retinal Microvascularization With OCT- Angiography in Patients With First-line Colorectal Cancer, Treated With Targeted Anti-angiogenic Therapy.
Essai Clinique (Centre Georges-François Leclerc)   12 février 2024
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Frontiers in oncology   10 janvier 2024
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC cancer   09 novembre 2023
PREDIGOSTEO: Osteopathy and Prevention of Gastrointestinal Side Effects of the Adjuvant Treatment FEC in Women Treated in Day Hospital for Breast Cancer
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
IMMUNOs-SBRT: An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Breast cancer (Tokyo, Japan)   10 août 2023
SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer
Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023   01 juin 2023
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
Journal of gastrointestinal oncology   10 avril 2023
Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": ESMO Open 3 (2018) e000375.
ESMO open   01 mars 2023